Critical State of "Remission-Recurrence" of Ulcerative Colitis

Launched by BEIJING HOSPITAL OF TRADITIONAL CHINESE MEDICINE · Nov 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called ulcerative colitis, specifically looking at patients who are currently in remission, meaning their symptoms are not active. The goal is to observe these patients for six months to see if and when their symptoms return. Researchers will collect information about the patients' health each month, including any symptoms they may experience and their mental well-being. They will also take samples of blood, urine, and stool to monitor their condition more closely.

To participate in this trial, potential candidates must be diagnosed with ulcerative colitis and currently in remission, based on specific medical tests. However, individuals with certain complications, incomplete medical records, or other serious health conditions will not be eligible. If you decide to join, you can expect regular check-ins for six months, where your health will be monitored, but there will be no treatments involved during this observation period. This study is important because it aims to better understand how ulcerative colitis can change over time and help improve care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who meet the criteria based on the clinical characteristics of ulcerative colitis patients in the "remission recurrence" critical state, combined with clinical symptoms, are diagnosed with ulcerative colitis through imaging, endoscopy, laboratory, and histopathological examinations;
• • Patients with comprehensive laboratory testing indicators.
• Exclusion Criteria:
• • Patients with incomplete case information records;
• • Patients who have not completed serological tests;
• • Complications including intestinal obstruction, intestinal perforation, toxic megacolon, and severe local stenosis;
• • Diagnosed or suspected patients with coexisting uncertain colitis, infectious or ischemic colitis;
• • Patients with coexisting local or systemic infections, any malignant diseases, or autoimmune diseases;
• • Merge primary diseases such as respiratory, circulatory, neurological, endocrine, and hematological disorders;
• • Individuals at risk of developing cancer;
• • regnant or lactating women.